BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 24387133)

  • 1. Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present.
    Casimiro MC; Velasco-Velázquez M; Aguirre-Alvarado C; Pestell RG
    Expert Opin Investig Drugs; 2014 Mar; 23(3):295-304. PubMed ID: 24387133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
    Ely S; Di Liberto M; Niesvizky R; Baughn LB; Cho HJ; Hatada EN; Knowles DM; Lane J; Chen-Kiang S
    Cancer Res; 2005 Dec; 65(24):11345-53. PubMed ID: 16357141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy.
    Nardone V; Barbarino M; Angrisani A; Correale P; Pastina P; Cappabianca S; Reginelli A; Mutti L; Miracco C; Giannicola R; Giordano A; Pirtoli L
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The activities of cyclin D1 that drive tumorigenesis.
    Ewen ME; Lamb J
    Trends Mol Med; 2004 Apr; 10(4):158-62. PubMed ID: 15059606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
    Said TK; Medina D
    Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.
    VanArsdale T; Boshoff C; Arndt KT; Abraham RT
    Clin Cancer Res; 2015 Jul; 21(13):2905-10. PubMed ID: 25941111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor binding protein-3 induces G1 cell cycle arrest with inhibition of cyclin-dependent kinase 2 and 4 in MCF-7 human breast cancer cells.
    Kim HS; Lee WJ; Lee SW; Chae HW; Kim DH; Oh Y
    Horm Metab Res; 2010 Mar; 42(3):165-72. PubMed ID: 19960406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis.
    Landis MW; Pawlyk BS; Li T; Sicinski P; Hinds PW
    Cancer Cell; 2006 Jan; 9(1):13-22. PubMed ID: 16413468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
    Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
    Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK4/6 inhibitors in breast cancer.
    Dukelow T; Kishan D; Khasraw M; Murphy CG
    Anticancer Drugs; 2015 Sep; 26(8):797-806. PubMed ID: 26053278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.
    Tang LH; Contractor T; Clausen R; Klimstra DS; Du YC; Allen PJ; Brennan MF; Levine AJ; Harris CR
    Clin Cancer Res; 2012 Sep; 18(17):4612-20. PubMed ID: 22761470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin D-CDK4/6 functions in cancer.
    Gao X; Leone GW; Wang H
    Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased G1 cyclin/cdk activity in cells overexpressing the candidate oncogene, MCT-1.
    Dierov J; Prosniak M; Gallia G; Gartenhaus RB
    J Cell Biochem; 1999 Sep; 74(4):544-50. PubMed ID: 10440924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
    Bindels EM; Lallemand F; Balkenende A; Verwoerd D; Michalides R
    Oncogene; 2002 Nov; 21(53):8158-65. PubMed ID: 12444551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
    Sweeney KJ; Swarbrick A; Sutherland RL; Musgrove EA
    Oncogene; 1998 Jun; 16(22):2865-78. PubMed ID: 9671407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin D1, cancer progression, and opportunities in cancer treatment.
    Qie S; Diehl JA
    J Mol Med (Berl); 2016 Dec; 94(12):1313-1326. PubMed ID: 27695879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells.
    Ahmad N; Adhami VM; Afaq F; Feyes DK; Mukhtar H
    Clin Cancer Res; 2001 May; 7(5):1466-73. PubMed ID: 11350919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK4 and CDK6 kinases: From basic science to cancer therapy.
    Fassl A; Geng Y; Sicinski P
    Science; 2022 Jan; 375(6577):eabc1495. PubMed ID: 35025636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
    Fåhraeus R; Laín S; Ball KL; Lane DP
    Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells.
    Sweeney KJ; Sarcevic B; Sutherland RL; Musgrove EA
    Oncogene; 1997 Mar; 14(11):1329-40. PubMed ID: 9178893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.